NeuroMetrix, Inc. (NURO) Bundle
A Brief History of NeuroMetrix, Inc. (NURO)
Company Background
Company Background
NeuroMetrix, Inc. was founded in 1996 and is headquartered in Waltham, Massachusetts. The company focuses on neurodiagnostic products aimed at the field of chronic pain and neurological diseases.
Product Development Milestones
NeuroMetrix has developed several critical products, including:
- Quell: A wearable device designed to relieve chronic pain, launched in 2015.
- DPNCheck: A point-of-care test for diabetic peripheral neuropathy, introduced in 2010.
- NeuroMetrix Pain Management Program: Initiated in 2017.
Financial Overview
As of the fiscal year ended December 31, 2022, NeuroMetrix reported:
- Total Revenue: $9.1 million
- Gross Profit: $5.4 million
- Operating Expenses: $10.5 million
- Net Loss: $5.1 million
Stock Performance
NeuroMetrix trades on NASDAQ under the ticker symbol NURO. As of October 2023, the stock price was approximately $1.50 per share. The market capitalization stood at approximately $20 million.
Recent Developments
In 2023, NeuroMetrix announced key partnerships to expand its product availability and patient outreach:
- Collaboration with healthcare providers for enhanced patient access to Quell.
- Launch of a new DPNCheck marketing campaign targeting diabetes clinics.
Table of Financial Performance
| Year | Total Revenue ($ millions) | Gross Profit ($ millions) | Operating Expenses ($ millions) | Net Loss ($ millions) |
|---|---|---|---|---|
| 2019 | 7.0 | 4.2 | 8.0 | 3.8 |
| 2020 | 6.8 | 3.8 | 9.1 | 5.3 |
| 2021 | 8.0 | 5.0 | 9.5 | 4.5 |
| 2022 | 9.1 | 5.4 | 10.5 | 5.1 |
Regulatory Approvals
NeuroMetrix has received FDA clearance for several of its products. Key approvals include:
- Quell: FDA-cleared in 2015 for over-the-counter sales.
- DPNCheck: Received FDA clearance in 2010.
Market Position
NeuroMetrix operates within the medical technology sector, specifically focusing on:
- Craniofacial electrotherapy stimulators.
- Wearable pain relief devices.
- Neuropathy diagnostics.
Research and Development Investments
In 2022, NeuroMetrix allocated approximately $1.5 million toward research and development. This investment focuses on enhancing existing technologies and exploring new therapeutic avenues.
A Who Owns NeuroMetrix, Inc. (NURO)
Company Overview
NeuroMetrix, Inc. (NASDAQ: NURO) is a publicly traded company that specializes in the development and commercialization of innovative medical devices for the treatment of chronic pain and other neurological disorders.
Shareholder Composition
The ownership structure of NeuroMetrix is comprised of institutional investors, retail investors, and company insiders. As of the latest reports, here is the breakdown of ownership:
| Ownership Type | Percentage Owned |
|---|---|
| Institutional Investors | 23.5% |
| Retail Investors | 56.2% |
| Company Insiders | 20.3% |
Major Institutional Investors
The following key institutional investors have substantial holdings in NeuroMetrix:
| Institution | Percentage Owned |
|---|---|
| BlackRock, Inc. | 8.4% |
| Vanguard Group, Inc. | 6.5% |
| Dimensional Fund Advisors LP | 4.8% |
Executive Team Ownership
The following members of NeuroMetrix's executive team hold significant shares in the company:
| Name | Title | Shares Owned |
|---|---|---|
| Shai N. Gozani, M.D., Ph.D. | CEO | 1,250,000 |
| Steven L. W. P. Wu, M.D. | COO | 600,000 |
| Charles F. W. Mu, M.D. | CFO | 400,000 |
Recent Stock Performance
The stock performance of NeuroMetrix has shown various fluctuations. Here is the latest financial data:
| Date | Closing Price | Market Cap |
|---|---|---|
| October 20, 2023 | $3.50 | $34.5 million |
| September 20, 2023 | $4.00 | $38.0 million |
| August 20, 2023 | $4.50 | $42.0 million |
Recent Developments
In the last quarter, NeuroMetrix reported an increase in revenue of 15% year-over-year, attributed to the launch of new products. The financial highlights are as follows:
| Quarter | Total Revenue | Net Income |
|---|---|---|
| Q3 2023 | $5.2 million | $1.1 million |
| Q2 2023 | $4.5 million | $900,000 |
| Q1 2023 | $4.2 million | $800,000 |
Future Outlook
Analysts project a compound annual growth rate (CAGR) of 10% for the next five years in the medical device sector, which includes companies like NeuroMetrix.
NeuroMetrix, Inc. (NURO) Mission Statement
Company Overview
NeuroMetrix, Inc. specializes in innovative diagnostic and therapeutic solutions focused on neurological disorders, particularly peripheral neuropathy and chronic pain.
Mission Statement
The mission of NeuroMetrix, Inc. is to transform the management of painful and debilitating neurological conditions through advanced technology, providing patients with efficient and effective solutions to enhance their quality of life.
Core Values
- Innovation: Commitment to continuous improvement and cutting-edge technology.
- Patient-Centricity: Focus on patients and their needs in product development.
- Integrity: Adherence to ethical principles in all business practices.
Current Financial Overview
NeuroMetrix, Inc. has shown a fluctuating financial performance over recent years. The following table summarizes key financial metrics from the latest fiscal year.
| Metric | Value (USD) |
|---|---|
| Revenue | 6.52 million |
| Net Loss | (3.23 million) |
| Operating Expenses | 8.12 million |
| Total Assets | 10.45 million |
| Total Liabilities | 4.67 million |
| Cash and Cash Equivalents | 1.40 million |
Market Position
As of 2023, NeuroMetrix, Inc. maintains a significant position within the neuromodulation and diagnostics market. The global market size for neuromodulation therapies was valued at approximately USD 6.5 billion in 2022 and is expected to grow at a CAGR of 13.9% through 2030.
Product Portfolio
NeuroMetrix has developed a range of products aimed at addressing specific health issues such as diabetic neuropathy. The following table showcases their key offerings:
| Product | Indication | Launch Year |
|---|---|---|
| SENSUS | Chronic Pain | 2015 |
| DPNCheck | Diabetic Peripheral Neuropathy | 2013 |
| Quell | Chronic Pain | 2015 |
Strategic Initiatives
NeuroMetrix has embarked on several strategic initiatives to fortify its market presence, including:
- Expansion into international markets to reach a broader patient base.
- Collaboration with healthcare providers to enhance product accessibility.
- Investment in R&D for next-generation neuromodulation technologies.
Recent Developments
In 2023, NeuroMetrix announced a partnership with major healthcare organizations to enhance the distribution of its products. They have also received regulatory approval for new indications for existing products, aiming to broaden their therapeutic applications.
Future Outlook
Moving forward, NeuroMetrix, Inc. aims to leverage its innovative technology and strategic partnerships to capture a larger share of the growing neuromodulation market, with a target revenue goal of USD 15 million by 2025.
How NeuroMetrix, Inc. (NURO) Works
Company Overview
NeuroMetrix, Inc. (NASDAQ: NURO) focuses on developing and commercializing innovative medical devices and therapies aimed at improving the treatment of chronic pain and other conditions. The company specializes in neurostimulation and digital medicine.
Product Lines
- Quell: An FDA-cleared wearable device for chronic pain relief.
- DPNCheck: A diagnostic tool for assessing diabetic peripheral neuropathy.
- NeuroMetrix Digital: A suite of digital health applications.
Market Focus
The company targets several markets, including:
- Chronic pain management
- Diabetes management
- Peripheral neuropathy
Financial Performance
As of Q2 2023, NeuroMetrix reported:
| Financial Metric | Q2 2023 | Q1 2023 | Q2 2022 |
|---|---|---|---|
| Revenue | $3.1 million | $2.9 million | $2.5 million |
| Gross Profit | $2.0 million | $1.7 million | $1.4 million |
| Net Loss | ($1.1 million) | ($1.2 million) | ($1.5 million) |
| Cash and Cash Equivalents | $6.5 million | $7.1 million | $5.0 million |
Research and Development
Research and development expenses for fiscal year 2022 amounted to:
| Year | R&D Expenses |
|---|---|
| 2022 | $2.3 million |
| 2021 | $1.9 million |
| 2020 | $1.5 million |
Regulatory Approvals
The company has achieved several significant regulatory milestones:
- FDA clearance for Quell in 2015.
- FDA clearance for DPNCheck in 2019.
- CE Mark certification for Quell in 2017.
Stock Performance
As of October 2023, the stock performance metrics include:
| Metric | Value |
|---|---|
| Current Price | $2.30 |
| 52-Week High | $4.10 |
| 52-Week Low | $1.50 |
| Market Capitalization | $30 million |
Partnerships and Collaborations
- Partnership with healthcare providers to expand product distribution.
- Collaboration with research institutions for clinical studies.
Future Outlook
Projected growth rates for 2024 suggest:
- Estimated revenue growth of 25% year-over-year.
- Expansion into international markets anticipated by Q3 2024.
How NeuroMetrix, Inc. (NURO) Makes Money
Product Sales
Product Sales
NeuroMetrix generates revenue primarily through the sales of its medical devices and products. The company’s flagship product, Quell, is a wearable neurostimulation device that aims to relieve chronic pain. For the fiscal year 2022, NeuroMetrix reported total revenues of $8.8 million.
Revenue Breakdown by Product Line
| Product Line | Revenue (2022) | Percentage of Total Revenue |
|---|---|---|
| Quell Devices | $6.2 million | 70.5% |
| Quell Accessories | $1.5 million | 17% |
| Clinical Trial Services | $1.1 million | 12.5% |
Distribution Channels
The distribution of products occurs through various channels:
- Online sales through NeuroMetrix's website.
- Retail partnerships with medical supply stores.
- Healthcare providers and clinics.
- Direct-to-consumer advertising.
Insurance Reimbursements
A significant portion of revenue is derived from insurance reimbursements. Quell is often covered by Medicare and various private insurance plans, enabling patients to afford the device. In 2022, insurance reimbursement accounted for approximately 45% of total sales.
Market Expansion Strategies
NeuroMetrix has implemented strategies to expand its market reach:
- Increasing direct-to-consumer marketing efforts.
- Participating in medical conferences to enhance visibility.
- Developing partnerships with healthcare providers to recommend products.
- Launching new products aimed at different segments of chronic pain management.
Research and Development (R&D) Investments
The company invests a portion of its earnings back into R&D to innovate and develop new products. In 2022, NeuroMetrix allocated $2.5 million for R&D, contributing to advancements in pain management technology.
Financial Performance Indicators
| Indicator | Value (2022) |
|---|---|
| Total Revenue | $8.8 million |
| Net Loss | -$4.1 million |
| Gross Profit Margin | 54% |
| R&D Expense | $2.5 million |
Future Outlook
NeuroMetrix’s growth strategy includes potential new product launches and expansion into international markets. The projected compound annual growth rate (CAGR) of the chronic pain management market is estimated at 7.4% from 2022 to 2030.
NeuroMetrix, Inc. (NURO) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support